Eliminating residual iPS cells for safety in clinical application

作     者：Shigeo Masuda Shigeru Miyagawa Satsuki Fukushima Nagako Sougawa Kaori Okimoto Chika Tada Atsuhiro Saito Yoshiki Sawa 

作者机构：Department of Cardiovascular Surgery Osaka University Graduate School of Medicine Osaka 565-0871 Japan 

出 版 物：《Protein & Cell》 (蛋白质与细胞（英文版）)

年 卷 期：2015年第6卷第7期

页      面：469-471页

核心收录：

学科分类：0710[理学-生物学] 0831[工学-生物医学工程（可授工学、理学、医学学位）] 0832[工学-食品科学与工程（可授工学、农学学位）] 1007[医学-药学(可授医学、理学学位)] 090602[农学-预防兽医学] 1002[医学-临床医学] 08[工学] 09[农学] 0906[农学-兽医学] 0703[理学-化学] 0836[工学-生物工程] 083203[工学-农产品加工及贮藏工程] 

基　　金：Japan Society for the Promotion of Science  JSPS  (15K10211) 

主　　题：Retinal Pigment Epithelium Teratoma Macular Degeneration Retinal Pigment Epithelium Cell Undifferentiated Cell 

摘      要：First-in-human clinical trial for age-related macular degen- eration using iPSC-derived retinal pigment epithelium （RPE） cells was conducted in 2014, showing no serious adverse effects to date, including tumor formation. This appears to be attributable to relatively small number of transplanted cells, and distinct morphology of RPE cells; it might be relatively easy to minimize contamination of undifferentiated cells. However,